Oncolytics Biotech

Oncolytics Biotech

Yahoo Finance • 30 days ago

Oncolytics' New U.S Patent Extends Pelareorep Manufacturing Protection Into 2044

(RTTNews) - Oncolytics Biotech Inc. (ONCY) has secured a new U.S. Patent that extends protection over the commercial manufacturing process of its investigational immunotherapy Pelareorep, marking another step in the company's long-term int... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech, Inc. SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunot... Full story

Yahoo Finance • 2 months ago

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest bat... Full story

Yahoo Finance • 3 months ago

Oncolytics Schedules Type C Meeting With FDA For Pelareorep In Anal Cancer

(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Monday announced that it has scheduled a Type C meeting with the U.S. Food and Drug Administration FDA on April 16, 2026, to discuss a potential registr... Full story

Yahoo Finance • 4 months ago

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financi... Full story

Yahoo Finance • 5 months ago

THE INFRASTRUCTURE REALIGNMENT: 5 Stocks Positioning for the 2026 Supply Imperative

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Equity InsiderMarket Intelligence Brief — WHAT’S HAPPENING: Gold above $5,000 per ounce[1]. The White House mobilized $12 billion for critical mineral stockpiling[2]. The F... Full story

Yahoo Finance • 5 months ago

Oncolytics surges on Fast Track status for pelareorep in colorectal cancer

[Colon cancer. Cancer attacking cell. Colon disease concept. 3d illustration] Mohammed Haneefa Nizamudeen * Oncolytics Biotech (ONCY [https://seekingalpha.com/symbol/ONCY]) is up ~15% in premarket trading Wednesday after announcing that... Full story

Yahoo Finance • 7 months ago

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways... Full story

Yahoo Finance • 7 months ago

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on momentum, entire subsectors have been left behind, c... Full story

Yahoo Finance • 7 months ago

UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality

VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This... Full story

Yahoo Finance • 7 months ago

The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality

VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This... Full story

Yahoo Finance • 8 months ago

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment... Full story

Yahoo Finance • 9 months ago

Oncolytics Biotech entered into $50M at-the-market sales agreement with BTIG

Oncolytics Biotech (NASDAQ:ONCY [https://seekingalpha.com/symbol/ONCY]) has established a new at-the-market equity financing agreement with BTIG, LLC. As disclosed in a Securities and Exchange Commission (SEC) filing [https://seekingalpha.... Full story

Yahoo Finance • 11 months ago

Large-cap biotech is a sector to watch for investors: Analysts

Wall Street is looking for new ways to park cash in healthcare names, and large-cap biotechs have begun to gain steam. This asset class differs from traditional large-cap pharmaceutical companies — typically with a $200 billion market cap... Full story

Yahoo Finance • 11 months ago

Oncolytics Biotech announces voting results from annual meeting

SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected all eight director nominees at its Annua... Full story

Yahoo Finance • 11 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and ex... Full story

Yahoo Finance • 11 months ago

Onc stock hits 52-week high at 309.25 USD

Onc stock reached a significant milestone, hitting a 52-week high of 309.25 USD. The $36.11 billion market cap company’s achievement reflects a robust performance over the past year, during which BeOne Medicines AG DRC, the company behind... Full story

Yahoo Finance • 12 months ago

Oncolytics Biotech regains compliance with Nasdaq listing requirements

SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a $34.64 billion market cap company, has regained compliance with Nasdaq’s minimum bid price requirement, according to a formal notice received Tuesday from the exchange’... Full story

Yahoo Finance • last year

Oncolytics Biotech reports positive biomarker data for pelareorep

SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage biotechnology company with a market capitalization of approximately $108 million, announced Wednesday that integrated biomarker analyses from multiple cl... Full story